Action Sandoz - 0SAN

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

22 718

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

Clôture Veille

0,00

Ouverture

Dernière Transaction

41.79667

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

0,00

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

9,65B

Bénéfice net

77M

Secteur

Med, Dental, Hosp Eq-whsl

Industrie

Med, Dental, Hosp Eq-whsl

Site Web

www.sandoz.com

Siège social

Rotkreuz, Che

Fondé

Sandoz Group Ag est coté dans le secteur Med, Dental, Hosp Eq-whsl de la London Stock Exchange avec le ticker 0SAN. Le dernier cours de clôture d'Sandoz était de CHF0,00. Au cours de la dernière année, les actions de Sandoz ont été négociées dans une fourchette de prix de CHF 0,00 à CHF 0,00.

Sandoz compte actuellement 0 actions en circulation.

Francisco Ballester to retire; Peter Stenico appointed President Region International

Francisco Ballester to retire; Peter Stenico appointed President Region International Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange...

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference MEDIA RELEASE Strong first...

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir®...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz share price?

The current share price of Sandoz is CHF 0,00

What is the 1 year trading range for Sandoz share price?

Sandoz has traded in the range of CHF 0,00 to CHF 0,00 during the past year

What is the reporting currency for Sandoz?

Sandoz reports financial results in USD

What is the latest annual turnover for Sandoz?

The latest annual turnover of Sandoz is USD 9,65B

What is the latest annual profit for Sandoz?

The latest annual profit of Sandoz is USD 77M

What is the registered address of Sandoz?

The registered address for Sandoz is SUURSTOFFI 14, ROTKREUZ, ROTKREUZ, 6343

What is the Sandoz website address?

The website address for Sandoz is www.sandoz.com

Which industry sector does Sandoz operate in?

Sandoz operates in the MED, DENTAL, HOSP EQ-WHSL sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
EUZEuropa Metals Ltd	1,55p (29,17%)	736,05k
SYMESupply@me Capital Plc	0,0042p (25,37%)	1,14B
CRTACirata Plc	23,95p (21,79%)	605,3k
ARKArkle Resources Plc	0,35p (16,67%)	1,6M
EQTEqtec Plc	0,605p (15,24%)	13,64M
BIOMBiome Technologies Plc	1,50p (-60,00%)	537,45k
ZEDZenova Group Plc	0,275p (-35,29%)	6,75M
UKOGUk Oil & Gas Plc	0,0115p (-34,29%)	1,61B
RCGHRc365 Holding Plc	1,05p (-30,00%)	14,77M
VIDVidendum Plc	46,65p (-24,76%)	6,62M
UKOGUk Oil & Gas Plc	0,0115p (-34,29%)	1,61B
NTVONativo Resources Plc	0,0015p (-16,67%)	1,55B
TRPTower Resources Plc	0,0275p (7,84%)	1,16B
SYMESupply@me Capital Plc	0,0042p (25,37%)	1,14B
LLOYLloyds Banking Group Plc	67,20p (1,97%)	272,15M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group Ag (0SAN)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Sandoz Group Ag

0SAN Dernières nouvelles

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

0SAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group Ag (0SAN) Cours

Sandoz Group Ag (0SAN)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Sandoz Group Ag

0SAN Dernières nouvelles

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

0SAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE